David Barrett

David B. currently serves as the Head of Engineered Small Molecules for the US and UK at Astellas Pharma Inc, a position held since April 2024. Prior roles at Astellas include Division Head and President of Mitobridge and Nanna Therapeutics from April 2022 to April 2024, and Executive Director, Science and Strategy Advisor from March 2020 to January 2022. David's extensive tenure at Astellas began in April 2005, featuring several senior roles focusing on research management, project coordination, and medicinal chemistry leadership. David's earlier experience includes senior positions at Fujisawa Pharmaceutical Co. Ltd, where drug candidate discovery in infectious diseases was a primary focus. Educationally, David holds a B.Sc and Ph.D. in Organic Chemistry from Newcastle University, with further studies at Stanford University and the University of Wisconsin-Madison.